Toshikiro Kimura
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Toshikiro Kimura has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Kazutaka Higaki
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1‐1‐1 Tsushima‐naka Okayama 700‐8530, Japan
3 shared publicationsKen‐Ichi Ogawara
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1‐1‐1 Tsushima‐naka Okayama 700‐8530, Japan
2 shared publicationsAkiko Ohkuma
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1‐1‐1 Tsushima‐naka, Okayama 700‐8530, Japan
1 shared publicationDaisuke Tsunashima
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1‐1‐1 Tsushima‐naka, Okayama 700‐8530, Japan
1 shared publicationHajime Toguchi
Formulation Development 1, Formulation Research Institute, Otsuka Pharmaceutical Co., Ltd., 224‐18 Ebino, Hiraishi, Kawauchi‐cho, Tokushima 771‐0182, Japan
1 shared publicationHitoshi Yamano
Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1‐1‐1 Tsushima‐naka, Okayama 700‐8530, Japan
1 shared publication
Latest Publications
- 1 August 1999
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 88 (8) , 830-834
Carrier‐mediated transport systems for glucose in mucosal cells of the human oral cavity
The in vitro uptake study was performed using the isolated cells of human oral mucosa, buccal and the dorsum of the tongue, to investigate the mechanisms of glucose uptake. The uptake of D-glucose was much larger in cells of the dorsum of the tongue than in buccal cells and was inhibited more extensively by 2-deoxy-D-glucose, a substrate of facilitative glucose transporters, than by alpha-methyl-D-glucoside, a specific substrate of SGLT1, suggesting the larger contribution of a facilitative transporter than Na(+)/glucose cotransporter. Furthermore, from the results of inhibition studies by several sugar analogues including maltose and D-mannose, GLUT1 and/or GLUT3 were suggested to take part in the glucose uptake by oral mucosa. Therefore, we have attempted to confirm the expression of glucose transporters on the oral mucosa by employing Western blotting. As a result, it was suggested that SGLT1, GLUT1, GLUT2, and GLUT3 are expressed in the epithelial cells of human oral mucosa.
- 1 August 1999
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 88 (8) , 830-834
Carrier‐mediated transport systems for glucose in mucosal cells of the human oral cavity
The in vitro uptake study was performed using the isolated cells of human oral mucosa, buccal and the dorsum of the tongue, to investigate the mechanisms of glucose uptake. The uptake of D-glucose was much larger in cells of the dorsum of the tongue than in buccal cells and was inhibited more extensively by 2-deoxy-D-glucose, a substrate of facilitative glucose transporters, than by alpha-methyl-D-glucoside, a specific substrate of SGLT1, suggesting the larger contribution of a facilitative transporter than Na(+)/glucose cotransporter. Furthermore, from the results of inhibition studies by several sugar analogues including maltose and D-mannose, GLUT1 and/or GLUT3 were suggested to take part in the glucose uptake by oral mucosa. Therefore, we have attempted to confirm the expression of glucose transporters on the oral mucosa by employing Western blotting. As a result, it was suggested that SGLT1, GLUT1, GLUT2, and GLUT3 are expressed in the epithelial cells of human oral mucosa.
- 1 March 1998
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 87 (3) , 295-299
Role of P-Glycoprotein as a Secretory Mechanism in Quinidine Absorption from Rat Small Intestine
The intestinal transport of quinidine was characterized in rat small intestine, using the Ussing-type chamber under short-circuited conditions. In the short-circuited condition, quinidine transport was predominantly secretory and the transport rate in jejunum was 3.5 times larger in the secretory direction than that in the absorptive direction. The secretion of quinidine was found to be dependent upon its concentration and to be via a carrier-mediated system in both jejunum and ileum. Although the kinetic characteristic of the carrier-mediated secretion of quinidine was very similar in jejunum and ileum, its contribution was much greater in jejunum because of a higher passive diffusion component in ileum. The secretion of quinidine, well-known as an inhibitor of P-glycoprotein, was inhibited significantly and its absorption was enhanced significantly by several substrates of P-glycoprotein including verapamil, diltiazem, and digitoxin in jejunum. These phenomena were also observed by the addition of 2,4-dinitrophenol. Furthermore, the voltage-clamp studies indicated that the inhibition of quinidine secretion occurred in the transcellular pathway. On the other hand, neither tetraethylammonium nor p-aminohippuric acid affected the transport of quinidine. Quinidine was also recognized to inhibit the secretion and to promote the absorption of substrates of P-glycoprotein, chlorpromazine, and verapamil. These results strongly suggest that quinidine is not only an inhibitor but also a substrate of P-glycoprotein and that the P-glycoprotein-mediated secretory flux acts as a barrier to quinidine absorption in the small intestine, especially jejunum.
- 1 March 1998
- Published by American Geophysical Union (AGU) in Journal of Pharmaceutical Sciences
- Vol. 87 (3) , 295-299
Role of P-Glycoprotein as a Secretory Mechanism in Quinidine Absorption from Rat Small Intestine
The intestinal transport of quinidine was characterized in rat small intestine, using the Ussing-type chamber under short-circuited conditions. In the short-circuited condition, quinidine transport was predominantly secretory and the transport rate in jejunum was 3.5 times larger in the secretory direction than that in the absorptive direction. The secretion of quinidine was found to be dependent upon its concentration and to be via a carrier-mediated system in both jejunum and ileum. Although the kinetic characteristic of the carrier-mediated secretion of quinidine was very similar in jejunum and ileum, its contribution was much greater in jejunum because of a higher passive diffusion component in ileum. The secretion of quinidine, well-known as an inhibitor of P-glycoprotein, was inhibited significantly and its absorption was enhanced significantly by several substrates of P-glycoprotein including verapamil, diltiazem, and digitoxin in jejunum. These phenomena were also observed by the addition of 2,4-dinitrophenol. Furthermore, the voltage-clamp studies indicated that the inhibition of quinidine secretion occurred in the transcellular pathway. On the other hand, neither tetraethylammonium nor p-aminohippuric acid affected the transport of quinidine. Quinidine was also recognized to inhibit the secretion and to promote the absorption of substrates of P-glycoprotein, chlorpromazine, and verapamil. These results strongly suggest that quinidine is not only an inhibitor but also a substrate of P-glycoprotein and that the P-glycoprotein-mediated secretory flux acts as a barrier to quinidine absorption in the small intestine, especially jejunum.